Disposition of epirubicin after intraarterial administration in Lipiodol to patients with hepatocellular carcinoma

Therapeutic Drug Monitoring

Volumn 18, Issue 5, 1996, Pages 537-543

  Dodds, Helen M ^a,b   Walpole, Euan T ^a   Rivory, Laurent P ^a   Strong, Russell W ^a   Pond, Susan M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

High performance liquid chromatography; Intraarterial intravenous pharmacokinetics; Lipiodol; Plasma epirubicin

Indexed keywords

7 DEOXYADRIAMYCINONE; ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN DERIVATIVE; DRUG METABOLITE; EPIRUBICIN; EPIRUBICIN GLUCURONIDE; EPIRUBICINOL; IODINATED POPPYSEED OIL; IOHEXOL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG FORMULATION; DRUG METABOLISM; EMULSION; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EPIRUBICIN; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGED; SUSPENSIONS;

EID: 0029763899     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199610000-00003     Document Type: Article

References (24)

1. Novell JR, Dusheiko G, Makham NI, Reddy K, Dick R, Hobbs KEF. Selective regional chemotherapy of unresectable hepatic tumours using lipiodol. HPB Surgery 1991;4:223-36.
2. Hoogewood HM. Hepatocellular carcinoma and liver metastases: diagnosis and treatment. Berlin: Springer-Verlag, 1993.
3. Tanaka K, Okazaki H, Nakamura S, et al. Hepatocellular carcinoma: treatment with a combination of transcatheter arterial embolization and percutaneous ethanol injection. Radiology 1991;179:713-7.
4. Konno T. Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in lipiodol. Eur J Cancer 1992;28:403-9.
5. Furuta T, Kanematsu T, Matsumata T, et al. Lipiodolization prolongs survival rates in postoperative patients with a recurrent hepatocellular carcinoma. Hepatogastroenterology 1990;37:494-7.
6. Horiguchi Y, Itoh M, Takagawa H, et al. Assessment of chemoembolization therapy for primary liver cancer using a stabilised adriamycin-lipiodol suspension. Cancer Chemother Pharmacol 1992;31:S60-4.
7. Okuda K. Hepatocellular carcinoma-recent progress. Hepatology 1992;15:948-63.
8. Ohishi Y, Uchida H, Yoshimura H, et al. Hepatocellular carcinoma detected by iodized oil: use of anticancer agents. Radiology 1985;154:25-9.
9. Yumoto Y, Jinno K, Tokuyama K, et al. Hepatocellular carcinoma detected by iodized oil. Radiology 1985; 154:19-24.
10. Konno T, Maeda H, Ewai K, et al. Selective targeting of anticancer drugs and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 1984;54:2367-74.
11. Nakamura H, Hashimoto T, Hiromichi O, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170:783-6.
12. Konno T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer 1990;66:1897-903.
13. Konno T. Targeting cancer chemotherapy for hepatocellular carcinoma by arterial administration of anticancer agents dissolved in lipiodol. Jpn J Cancer Chemother 1987;17:373-80.
14. Robert J. Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet 1994;26:428-38.
15. Dobbs NA, Twelves CJ, Rizz P, et al. Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity. Cancer Chemother Pharmacol 1994;34:405-10.
16. Robert J. Extraction of anthracyclines from biological fluids for HPLC evaluation. J Liq Chromatogr 1980;3:1561-72.
17. Johnson PJ, Kalayci C, Dobbs N, et al. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 1991;13:120-7.
18. Robert J, David M, Granger C. Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug. Cancer Chemother Pharmacol 1990;27:147-50.
19. Robert J, Vrignaud P, Nguyen-Ngoc T, Lliadis A, Mauriac L, Hurteloup P. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat Rep 1985;69:633-40.
20. Pannuti F, Camaggi CM, Strocchi E, et al. Intrahepatic arterial administration of 4′epidoxorubicin (epirubicin) in advanced cancer patients: a pharmacokinetic study. Eur J Cancer Clin Oncol 1986;22/11:1309-14.
21. Lee K, Chan K, Leung WT, et al. Disposition of epirubicin in an oily contrast medium after intravenous and intrahepatoarterial administration in liver cancer: a preliminary report. Eur J Drug Metab Pharmacokinet 1992;17:221-6.
22. Nakamura H, Mitani T, Murakami T, et al. Five-year survival after transcatheter chemoembolization for hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33(suppl): S89-92.
23. Leung WT, Shiu WCT, Leung N, et al. Treatment of inoperable hepatocellular carcinoma by intra-arterial lipiodol and 4′-epidoxorubicin. Cancer Chemother Pharmacol 1992;29: 401-4.
24. Yoshikawa M, Saisho H, Ebara M, et al. A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33(suppl):S149-52.